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REVIEW
Selective drug delivery approaches to lesioned brain through blood brain barrier
disruption
Zahraa S. Al-Ahmady
Nanomedicine Lab, Division of Pharmacy and Optometry, Faculty of Biology, Medicine and Heath, University of Manchester, UK
ABSTRACT
Introduction: The development of therapeutics for central nervous system (CNS) disorders is still
considered a challenging area in drug development due to insufficient translocation through the
blood-brain barrier (BBB). Under normal conditions, BBB restrict the penetration of more than 98% of
blood-borne molecules including drugs to the CNS. However, recent research findings have proven that
the nature of the BBB is altered in several neurological conditions. This complexity encourages revisiting
drug delivery strategies to the CNS as this can give a wide range of opportunities for CNS drug
development.
Areas covered: This review focuses on nanotechnology-based drug delivery platforms designed for
selective recruitment into the lesioned brain by taking advantages of BBB disruption that is associated
with certain neurological conditions.
Expert opinion: Current CNS therapeutic strategies do not fully address the pathophysiological
adaptation of BBB in their design. The lack of selective delivery to the brain lesions has been the
culprit behind the failure of many CNS therapeutics. This highlighted the need for smart designs of
advanced drug delivery systems that take advantage of BBB structural changes in CNS diseases.
Recently, promising examples have been reported in this area, however, more work is still required
beyond the preclinical testing.
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1. Challenges of CNS drug delivery: the BBB
obstacle
The development of therapeutics for central nervous system
(CNS) disorders is a significant challenge owing to the privi-
leged protective nature of the brain mediated by the blood–
brain barrier (BBB). Experimental evidence of restrictive move-
ment of solutes from blood to brain tissues dated back to
1880s when Paul Ehrlich first described that many acidic dyes
injected into peripheral blood did not stain the CNS [1].
However, it was only in the late 1960s that Reese and
Karnovsky found out that the barrier was localized to the
endothelium by electron-microscopy studies [2]. Several
other studies that followed showed that substances can have
variable ratios on both sides of the BBB and those ratios can
be altered in disease situations [3,4]. Thus, BBB emerged as a
complex and a dynamic process that controlled the exchange
of substances between the blood and CNS. This process was
found to be different between substances and was adaptable
to pathological conditions [5].
Unlike the microvasculature in the periphery, brain
endothelial cells (BECs) are interconnected by tight junctions
(TJs) that seal spaces between endothelial cells [6]. TJs form a
physical barrier for paracellular transport and limit brain pene-
tration of large hydrophilic macromolecules that would other-
wise readily cross the endothelial cells (Figure 1) [7]. Therefore,
paracellular route has very limited contribution to the entry of
substances into the brain. This is usually for molecules with
very long half-lives, small volume of distribution, and very
potent CNS effect. Antibodies and erythropoietin (EPO) are
examples of that [8].
The lipid nature of BECs allows the entry of small lipophilic
molecules with molecular weight <400 Da by a process known
as passive diffusion (Figure 1) [9]. Passive diffusion is non-
saturable process for small lipophilic molecules. The degree
by which a substance can undergo passive diffusion also
depends on other factors e.g. pharmacokinetic properties,
hydrogen bonding, and charge. This process is usually mea-
sured by the octanol/water partition coefficient, ideally
between 10:1 and 100:1 [9]. Examples of marketed drugs
that access the brain by this pathway are steroids and diphen-
hydramine [10,11].
Active transporters, on the other hand, enable the move-
ment of substances such as essential nutrients, ions, and other
endogenous substances into the brain against their concen-
tration gradient in an energy-dependent manner. Many ther-
apeutic molecules utilize this pathway to get access into the
CNS such as opioid analgesics, cardiac glycosides, and calcium
channel blockers [12].
Another important feature of BECs is the limited transcy-
totic vesicles that restrict the diffusion and the transport of
most hydrophilic molecules into the brain except certain
molecules that utilize carrier-mediated transporters (CMT)
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(Figure 1) [8]. This explains how glucose, electrolytes, vita-
mins, and some peptides have the ability to cross the brain
at 10–100 times faster rate than would be predicted based
on their physicochemical characteristics [5]. A classical
example of CMT is the glucose transporter (GLUT1) that
facilitates bidirectional diffusion of molecules down a con-
centration gradient from a high-to-low concentration. An
example of CNS drugs that enter the brain by this pathway
is the anti-Parkinsonian drug L-dihydroxyphenylalanine (L-
DOPA) that utilizes large-amino acid transporters 1 (LAT-1)
to get access into the brain [13].
Receptor-mediated transporters (RMT) facilitate the trans-
port of specific molecules into and/or outside the brain
(Figure 1). The source of insulin in the brain is coming from
peripheral origin. Insulin gets access to the brain through
insulin receptor (IR) that facilitates endocytosis from blood to
the brain only [14]. Similarly, transferrin (Tf) transport to the
brain is mediated by Tf receptor (TfR). TfR is expressed on both
luminal and abluminal surface of BECs and therefore, it med-
iates both the endocytosis of TfR from blood to brain direc-
tion, in addition to the efflux transfer of apotransferrin from
brain back to the blood [15,16]. In contrast, FC receptor allows
unidirectional transport of IgG molecules from brain to
blood [17].
Highly charged molecules or molecules that can bind to
glycoproteins are likely to enter the brain through vesicle-
based processes known as adsorptive endocytosis/transcytosis.
These vesicles are either trafficked to lysosomes or routed all
the way from luminal cell membrane to abluminal membrane
giving a route to the passage of substances across the BBB. An
important feature of this process is that it is different from
classical saturated transporters in a way that increasing the
concentration of ligands can further enhance the uptake. In
fact, in extreme cases, this pathway can result in BBB damage
due to coalescing of vesicles to form channels through the BECs
[18]. Tat peptides act through this mechanism due to their
highly charged nature [19].
Despite getting access into the brain, CNS drug delivery
can still be compromised by the polarized expression of
efflux transporters that shuttle out many drug molecules
from the brain back into the circulation. These can be either
energy dependent that belong to ATP-binding cassette
(ABC) gene family such as P-glycoprotein (P-gp) and breast
cancer resistance protein (BCRP) or energy independent that
belong to the solute carrier transporter gene family such as
organic anion transporters polypeptides (OATPs/Oatps).
P-gp, which is known as multidrug resistance, has received
excessive attention, but it is just one of the many efflux
transporter in the ABC gene family. Efflux transport pro-
cesses could be considered as natural protective mechan-
isms of the brain specially designed to prevent brain
exposure to drugs and foreign molecules [20]. Thus, defect
in efflux transporters can contribute to diseases, as in the
case of reduced brain-to-blood efflux of amyloid β (Aβ)
peptide that contributes to elevated Aβ levels in the brain
[21,22]. P-glycoprotein has a very broad substrate profile
and thus considered a formidable obstacle to CNS drug
delivery. These include but not restricted to calcium channel
blockers, antibiotics, cardiac glycosides, anticancer drugs,
anti-epileptics, antidepressants, and immunosuppressants
[23]. Example of marketed drug that act by inhibiting efflux
transporters is verapamil for seizure treatment. Given the
broad nature of these inhibitors, long-term use of efflux
inhibitors can result in interference with endogenous sub-
stances and may cause neurotoxicity [23].
Furthermore, BECs are enclosed by and in continuous cross
talk with a variety of cells (Figure 1). The abluminal surface of
BECs is supported by pericytes and surrounded by 20–200-nm
thick vascular basement membrane (BM) composed of three-
dimensional networks of proteins predominantly collagen IV,
laminins, nidogen, and heparan sulfate proteoglycans secreted
by vascular and neural cells [24,25]. The composition of the
BM is largely dependent on the location of the blood vessels.
Large parenchymal arteries and arterioles are surrounded by
two principally different BMs, the endothelial and parenchy-
mal BMs. Patchy distribution of endothelial BM is observed
surrounding postcapillary venules and this correlates with sites
of lymphocytes extravasation [26]. This structure is further
encased by astrocytic end feet cellular processes that
ensheathe the blood vessels as well as neuronal synapses
[27]. The association of endothelial cells, neural cells, and
extracellular matrix (ECM) forms the neurovascular unit that
plays a crucial role in modulating BBB integrity and drug
penetration into the brain [5]. These structural features allow
BECs to adapt constant cross talk with astrocytes, microglia,
neurons, pericytes, and peripheral immune cells in order to
refine BBB function to serve the brain needs [5].
BBB structure presents both physical and biochemical
barrier that significantly limit the entry of therapeutic mole-
cules into the brain and, therefore, reduce treatment effi-
cacy [28]. Figure 1 summarizes the structural features of BBB
in healthy conditions and the mechanisms of molecular
Article highlights
● The blood brain barrier (BBB) is the single most important limiting
factor that restricts the access of more than 98% of pharmaceutical
drugs to the brain.
● Brain endothelial cells (BECs) are unique for being interconnected by
tight junctions that seal spaces between BECs and have very limited
transcytotic vesicles and therefore, restrict the transport of hydro-
philic molecules to the brain.
● BBB functions and structure are not fixed, but in a dynamic change to
respond to CNS needs during natural development and disease
conditions. Changes to BECs structural features and transporter sys-
tems are widely reported in several brain disorders and contribute to
BBB hyperpermeability.
● Lesioned brain is defined as an injury or disease in an area of the
brain due to infection, problems with immune system, injury, disrup-
tion in blood supply, tumor, etc.
● Despite the reported disruption to BBB in different models of
lesioned brain, a little or no increase in permeability to small ther-
apeutic molecules (< 1000 Dalton) has been observed.
● Recent studies using nanoparticles-based delivery systems showed
clearly that it is possible to selectively target the lesion area in the
brain when injected intravenously in preclinical animal models. These
observations suggested that the selective brain accumulation is
mediated by BBB hyperpermeability, a phenomenon that could be
very similar to the well-known enhanced permeability and retention
(EPR) effect observed in solid tumors.
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transport across the BBB. Apart from the restrictive role of
BBB, the compromised CNS drug delivery could also be
related to drug factors. Among these are the drug molecu-
lar weight, the drug solubility, and the surface properties
(such as the charge) [29]. Brain–blood ratio is used as an
indication of the drug access into the brain. A ratio exceed-
ing 1.0 indicates that the drug molecules have free access
into the brain. On the other hand, a ratio between 0.3 and
0.5 represents sufficient brain access and a ratio of less than
0.1 indicates no access [20]. Based on the above, it is very
clear that the BBB is the single most important factor limit-
ing the treatment of lesioned brain. In fact, it has been
estimated that BBB restricts brain access of more than
98% of therapeutic molecules.
2. Strategies to enhance CNS drug delivery
Several approaches have been principally investigated to
enhance the prospective BBB penetration of therapeutic mole-
cules. The rationale for these approaches is largely variable
and can be summarized by the following, taking advantage of
certain transport system, enhancing transmembrane diffusion,
increasing enzymatic resistance, and improving pharmacoki-
netic profile. Care must be taken when considering structural
modification as this can often results in unexpected observa-
tions. Although this area of drug development is very promis-
ing, it is at the same time very difficult and challenging as the
structural modification processes can often interfere with the
transport machinery of interest resulting in drug–brain pene-
tration through different routes. These strategies have been
thoroughly reviewed before [5,12,13]; however, below is a
brief summary of the different categories implemented.
2.1. Intracerebral administration
For more specific and effective delivery of therapeutics to spe-
cific regions of the brain, direct injection/implantation into the
region of interest using stereotactic coordinates and/or contin-
uous intraventricular infusion of the drug into the brain tissue
are usually applied. Promising results have been reported using
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Figure 1. The BBB is situated at the walls of the blood vessels that supply blood to the central nervous system. The BBB is composed of a network of different cells
that form the neurovascular units. These include astrocytes, microglia, pericytes, neurons, and brain endothelial cells with highly regulated tight junctions. Because
of this complex structure, the transport of molecules through BBB is highly restricted to specific mechanisms that would apply to very limited molecules. 1) CNS
delivery of large and hydrophilic molecules is almost entirely excluded by the physical presence of tight junctions; while 2) lipid-soluble molecules can diffuse across
the brain endothelial cell passively. Other possible mechanisms to cross BBB include; 3); carrier-mediated transport (specific for certain molecules such as glucose, 4)
receptor-mediated transport (e.g. insulin through insulin receptor (IR) and transferrin mediated by transferrin receptor (TfR), and 5) adsorptive transcytosis/
endocytosis for the transport of cationic molecules. 6) Despite getting access into the brain, CNS drug delivery can still be compromised by the polarized expression
of efflux transporters that shuttle out many drug molecules from the brain back into the circulation (e.g. P-gp, OATPs).
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this approach in clinical trials for Parkinson’s disease for example
[30,31]. Although this method is clearly the most effective in
overcoming the BBB obstacle, there is a potential risk of several
unwanted side effects such as damage to the healthy brain
tissue along the needle track, CNS toxicity due to excessive
drug concentration, susceptibility to infections, and general
risks associated with anesthesia and surgery [32–34].
2.2. Intrathecal injection
Other less invasive approaches currently in clinical use include
the direct injection into the cerebrospinal fluid (intrathecal
injection). There are very few drugs that approved for such
approach and the drug site of action here is the CNS surface
rather than the brain parenchyma. Intrathecal chemotherapy
is in clinical use for prophylaxis and treatment of CNS involve-
ment by lymphoma or leukemia [35].
2.3. Intranasal route
This approach utilizes the nose submucous olfactory region
as a potential route of drug transport from the nasal
mucosa into the brain [36]. Several parameters need to be
considered for this approach: (1) the capability of drug to
transport across the nasal epithelium, (2) drug penetration
through the arachnoid membrane that separates nasal sub-
mucous region from olfactory (cerebrospinal fluid) CSF
space. Thus, the properties that control drug transport
from nose to olfactory CSF are very close to those determin-
ing drug transport across the BBB. Based on that, small
lipophilic molecules can best benefit from this approach in
the absence of local disruption to the nasal mucosa [36,37].
2.4. BBB disruption
Besides the direct intracranial administration of therapeutics
to the brain, there have been considerable efforts to
enhance CNS drug delivery by applying transient BBB dis-
ruption techniques. A very widely used technique in this
area is the intracarotid arterial infusion of 2 molar concen-
tration of mannitol that has poor diffusion into the brain.
Mannitol is a hyperosmotic solution that causes the
endothelial cells to shrink and, therefore, stretches the TJs.
This approach commonly used to enhance delivery of che-
motherapeutic drugs to brain tumors; however, the success
of this technique can be dependent on the differential
sensitivity of the blood–tumor barrier to disruption com-
pared to the surrounding healthy brain tissues [38]. The
use of ultrasound waves to open pores in the BBB is
another area of active research [9]. The frequencies of ultra-
sound waves used for this purpose are 28 kHz to 8 MHz for
rodents studies; however, the recommended frequencies for
clinical use are 0.2–1.5 MHz [32]. Thus, intravenous injection
of microbubbles is typically used to reduce the power
necessary to disrupt the BBB [39]. BBB disruption by this
method is usually transient that lasts usually few hours to
<1 day, depending on the brain region, provided that no
permanent tissue damage occurs [40].
2.5. Inhibition of BBB efflux transporters
Efflux transport systems (e.g. P-gp, BCRP) act at the luminal
surface of EC to expel molecules back into the circulation and,
therefore, represent a major restrictive feature of BBB against
CNS drug delivery as explained earlier. Consequently, inhibi-
tion of those efflux mechanisms would therefore offer great
opportunity to increase the amount of drug that reaches the
brain. However, the beneficial effect of this approach is con-
troversial in terms of safety and efficiency due to the broad
nature of these inhibitory molecules. Therefore, recent efforts
have been directed toward targeting discrete signaling path-
ways to have specific action rather than global inhibition of
these efflux pathways. For more details, please refer to recent
excellent reviews that cover this in more details [12,41].
2.6. Molecular modifications
Early efforts of structural modification of compounds were
directed toward increasing lipid solubility to enhance passive
diffusion across the BECs. However, studies over the years
have proved that this approach is difficult to implement.
Increasing the lipophilic nature of drug molecules, for exam-
ple, can, on the contrary, restrict the ability to reach the CNS
because of increased uptake by peripheral organs or entrap-
ment within the lipid membrane [42]. In fact, until now, there
is no FDA-approved CNS drugs that have increased CNS accu-
mulation by enhancing lipid solubility. Thus, efforts have been
shifted toward the use of medicinal chemistry to enhance
brain uptake of water-soluble drugs through the adoption of
BBB influx transporters to enhance CNS drug delivery.
Currently, there are two main trends in this adoption process:
first, targeting RMT such as BBB IR or TfR through engineering
of bispecific antibodies or molecular Trojan horses. Second,
engineering drugs have affinity to an endogenous BBB CMT
system that normally facilitates the entry of peptides, vitamins,
or hormones into the brain. To enhance drug transfer by RMT,
conjugation to peptidomimetic monoclonal antibody (mAb)
that can traverse the BBB through specific receptor is prefer-
able to the use of endogenous substrates such as insulin or
TfR. This is to avoid any unwanted slide effects (hypoglycemia
in the case of insulin) or competition on the binding site (high
concentration of endogenous TfR 25 µmol/L) [37]. EPO is a
neurotrophic factor that has limited brain penetration. Re-
engineering EPO by conjugation with human IR (HIR) mAb
produced a brain-accessible form of EPO at 2.1% of ID/100 g
of brain [43]. The enhanced brain delivery through CMT was
discovered serendipitously for anti-Parkinson drug L-DOPA
that does not cross the brain by passive lipid diffusion. L-
DOPA on the other hand is a large neutral amino acid that
utilizes LAT1 to cross the BEC. Once in the brain, L-DOPA is
decarboxylated to the active form dopamine [44,45].
Gabapentin is another example of water-soluble drug that
gets access into the brain through LAT1 system [46]. OATPs
also play an important role in the transport of opioid analge-
sics and pain management [47]. Care must be taken to con-
sider alterations in the pharmacokinetic profile of antibodies
after the reengineering process, the possibility of clearance by
peripheral organs expressing these receptors and changes in
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the influx transporters expression in different neurological
disorders.
3. Modifications of the BBB in lesioned brain
It is now well established that BBB functions are in dynamic
response to CNS needs during natural development and dis-
ease conditions. These changes involve both the structure and
the transporter systems, with the latter being more sensitive in
many pathological conditions. BBB disruption is a serious
complication in many diseases of the CNS as summarized in
Table 1. This could be a result of extrinsic factors (multiple
sclerosis [MS] and [48,49] meningitis [50]) or due to intrinsic
factors as in the case of ischemic stroke [51–53], Alzheimer
disease (AD) [54,55], traumatic brain injury (TBI) [56], seizures
[57,58], diabetes [59], chronic pain [60], and many others [61].
In many of these disorders, the damage to BBB is clearly a
secondary effect to the primary insult as in the case of TBI and
stroke; however, in other conditions as in the case of MS and
AD, it remains unclear if BBB disruption has a role in the
disease initiation process [24]. Most of the research has
focused on the role of the TJ as the main contributor to BBB
disruption. However, enhanced expression of other transcellu-
lar pathways can happen as well and may even be the dom-
inating factor to BBB disruption [62,63].
During ischemic stroke, there is a strong evidence from
preclinical [62,63,66] and clinical [67,68] studies that BBB
integrity is impaired. Compromised BBB function leads to a
biphasic increase in permeability and uncontrolled entry of
molecules into the brain. In normal conditions, endothelial
cells, through tightly regulated transcellular transport func-
tions and TJ proteins [63], are the primary regulators of the
entry of blood-borne molecules into the brain (Figure 2). The
contribution of these two pathways to BBB hyperpermeability
after ischemic stroke is controversial [56]. However, the most
accepted model of hyperpermeability is early phase (within
6 h) increase in endothelial vesicles (termed caveolae), fol-
lowed by TJ proteins disassembly and loss of integrity at a
later point (>24 h poststroke). This model is supported by
recent evidence from transgenic mouse strain study in which
endothelial TJs were labeled with eGFP, allowing the dynamics
of TJs to be monitored in vivo in real time [63]. This model is
also supported by recent evidence from rats ischemic stroke
model, which proved that BBB opening to macromolecules
(transcellular route) precedes permeability to small ions (para-
cellular opening) [69]. Moreover, the reported BBB disruption
is significantly exacerbated when combined with other comor-
bidities; however, the consequence of events contributing to
BBB hyperpermeability has not significantly changed [62].
Similarly, MS lesions are characterized by severe inflamma-
tion, loss of barrier, and infiltration of monocytes [70].
Disruption of the BBB has been proved in preclinical in vivo
studies of both acute and chronic MS using gadolinium (Gd)
contrast enhanced MR [71,72]. In MS, BECs are phenotypically
modulated to express endothelial cell adhesion molecules that
enhance the inflammatory cells migration through the dis-
rupted BBB. Infiltration of the brain by inflammatory cells
triggers MS inflammatory cascade through the production of
inflammatory cytokines and chemokines (e.g. IL1β, INFγ, and
TNFα) within the cerebral interstitium. In addition, BBB disrup-
tion in MS has also been reported to involve both structural
remodeling and reduced expression of TJ proteins [73].
In addition to the mechanisms described above, the loss of
BBB integrity can also be a result of upregulation of proteolytic
enzymes that cause the degradation of vascular BM and ECM
proteins. The precise mechanisms behind that are not fully
elucidated; however, the significant upregulation of matrix
metalloproteinases (MMPs) and plasminogen activator sys-
tems are the main triggers. Different enzymes or cytokines
have been reported before to activate MMPs through cleavage
of pro-domains into the active forms including membrane-
type 1-MMP (MT1-MMP) and plasmin. Moreover, the high
Table 1. Pathological conditions with BBB disruption.
Disease Evidence of BBB disruption from clinical and preclinical studies References
Extrinsic factors
MS ● Gd-enhanced MRI
● Immune cells infiltration
● Loss of TJ protein in postmortem samples
[48,49]
Infections – e.g. meningitis ● Enhance proteases activity (e.g. MMP9) and immune cells infiltration [50]
Intrinsic factors
Ischemic stroke – hypoxia, glial activation, and
macrophages infiltration
● Neuroimaging
● Immune cells infiltration
● Upregulation of E-selectin and P-selectin
[51–53]
TBI – edema and hemorrhage ● Biphasic increase in BBB permeability [56]
Small vessels disease – e.g. diabetes ● Pericytes loss due to oxidative stress mediated by high glucose level [59]
AD ● Increase in BBB permeability measured by CSF albumin levels was observed in AD patients
and correlated with disease progression
● Decrease the levels of amyloid β efflux transporter from brain to blood such as Pgp and LRP1
in patients with AD
● Inflammation-induced pericytes loss and disruption to BBB
[5,54,55]
Chronic pain ● TJ disassembly [60]
Parkinson’s disease (PD) ● Decrease in P-gp as demonstrated in PET imaging [64,65]
Epilepsy ● Albumin depositions in postmortem brain tissues of patients with seizures and epilepsy
● Elevation of P-gp expression
● Seizures associated with other condition of BBB damage e.g. stroke and trauma
[57,58]
LRP1: Low-density lipoprotein receptor-related protein 1; BBB: blood–brain barrier; AD: Alzheimer disease.
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level of inflammatory cytokines and reactive oxygen species
produced after certain neurological conditions (e.g. stroke) can
stimulate MMP9 section and activate pro-MMP9 [50,74].
Because of BBB disruption, leakage of plasma products
and infiltration of immune cells (monocytes, neutrophils,
and macrophages) into the brain parenchyma will occur
which can further aggravate the BBB damage by secreting
proteases and inflammatory cytokines. Consequently, ECM
receptors expression is altered, and this has a crucial effect
on the homeostasis of NVU cells such as survival, prolifera-
tion, and migration [74]. These changes explain the loss of
the cells in contact with the vessels due to the loss in
receptors that anchor these cells in place. In experimental
model of ischemic stroke, microvasculature coverage of
astrocytes gradually reduced to 74% in 4 h, 16% in 12 h,
and almost none 48 h after ischemia [75]. This also asso-
ciated with migration of pericytes away from blood vessels
breaking through BM that surrounds them [76]. On the
contrary, microglial cells were observed to migrate in
close proximity to the microvasculature [77].
It can, thus, be inferred from above that there are several
mechanisms by which the BBB can be compromised in
lesioned brain, thus highlighting the possibility that diseased
BBB can itself act as a gate for therapeutic access. For this
review, I would like to discuss the role of BBB hyperperme-
ability to enhance selective drug accumulation in the brain by
considering two pathological conditions, stroke and MS, since
several promising examples have been demonstrated with
these two conditions before. An effective drug delivery
approach in those situations should be able to selectively
penetrate areas of BBB hyperpermeability as compared to
other brain regions where BBB permeability is unaffected.
4. How to take advantage of BBB disruption to
enhance drug delivery to the brain?
Pharmacological transient disruption of the BBB is a widely
used strategy to enhance drug delivery to the brain. A tradi-
tional example is through the osmotic opening of BBB using
mannitol that is used in the treatment of certain CNS cancers
[78] and the use of ultrasound waves to open transient pore in
the BBB to enhance drug penetration [79]. The downside of
such strategies lies in the lack of selectivity meaning that not
only the potential therapeutics could get access into the brain
but also any other circulating substances that are normally
excluded by the BBB can get access to the CNS with poten-
tially harmful consequences.
Recent studies have shown that pathological BBB disrup-
tion in models of Alzheimer’s and MS resulted in little or no
increase in permeability to small therapeutic molecules
(<1000 Da) [80]. This observation could also be true for ther-
apeutic approaches of BBB disruption, since, in these situa-
tions, the disrupted BBB could still retain some degree of
barrier selectivity. This, in addition to the suboptimal pharma-
cokinetic nature of many drug molecules, means that attempt-
ing to therapeutically disrupt the BBB can have uncertain
consequences.
Based on the above, the dilemma of therapeutic drug
delivery in lesioned brain can be stated in two parts: (1)
currently, it is proven that BBB is disrupted in lesioned brain
and this has serious consequences on pathological evolution,
and (2) the BBB disruption does not improve the delivery of
low molecular weight molecules into the diseased brain tissue.
Since conventional drug delivery methods have very lim-
ited access to the brain, systemic high doses are often
required for a drug to reach therapeutic levels in the lesioned
CNS. This carries the obvious risk of collateral damage due to
unnecessary exposure of normal healthy tissues.
5. Promising drug delivery approaches in other
conditions: the cancer story
Over the past few decades, nanotechnology-based drug deliv-
ery systems proved to offer superior therapy control com-
pared to small molecule drugs in several pathological
conditions [81,82]. Cancer therapy [83–85] and inflammatory
diseases [86,87] are the most promising applications so far,
where several formulations have already made it into clinical
practice [88]. Among those drug delivery systems, liposomes
and other polymeric nanoparticles have a great potential since
they dramatically change the pharmacokinetics and the phar-
macodynamics profiles of the encapsulated drugs, reduce the
drug-associated toxicity, and, therefore, improve the patients’
experience. An important parameter behind the improved
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Brain parenchyma
Blood vessel lumen
Tight junction 
proteins
Ischemic insult
Normal BBB Disrupted BBB
Transcytosis 
vesicles
Figure 2. Structural changes to BBB after ischemic stroke: Several experimental ischemic stroke models reported qualitative and quantitative increase in transcytotic
transport across the BBB and tight junction strands disassembly. These structural changes contribute to the BBB hyperpermeability reported after ischemic stroke.
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therapeutic outcome of these delivery systems is the increase
in blood circulation time. AmBisome® and Doxil® are exam-
ples. In the case of AmBisome (liposomal amphotericin), the
long blood circulation is due to the rigid lipid nature of the
liposomal formulation [89]. On the other hand, the long circu-
lation time of Doxil® (liposomal doxorubicin) is provided by
surface coating of nanoparticles with the hydrophilic polymer
polyethylene glycol [90]. As a result of the long blood circula-
tion, there is a greater chance to accumulate passively in
tumor tissues as a result of the latter’s hyperpermeable
blood vessels and impaired lymphatic drainage. This phenom-
enon is collectively known as the enhanced permeability and
retention (EPR) effect [91,92]. This effect was first described by
Maeda et al. [91] and since then, it is believed to be behind
the selective targeting of the tumor and inflammatory tissues.
The observed hyperpermeability has been shown to be
mediated through one or more of the following pathways:
endothelial membrane fenestrations [93], gaps in the blood
vessels [93], and the transcellular vesicular transport system
(caveolae) [94].
Similarly, hyperpermeability of BBB is widely reported in
preclinical and clinical studies in several models of lesioned
brain [5]. Recent studies in middle cerebral artery occlusion
model of ischemic stroke reported BBB hyperpermeability
[62,63,69,95] due to a qualitative and a quantitative increase
in transcytotic transport across the BBB in the early phase after
ischemia in addition to more than 30% opening of TJ strands
that usually follow at later stages [63]. Based on the above,
there is a clear resemblance between the BBB endothelial cells
structural adaptation in lesioned brain and what has been
reported in cancer and inflammatory conditions. This shows
that nanotechnology drug delivery systems can be equally
efficient in achieving selective and enhanced drug delivery
to the lesioned brain as compared to what is seen in cancer
and inflammation. It is important to mention here that for
brain tumors, the beneficial role of EPR effect to enhance
drug delivery is controversial. This is because EPR effect is
usually observed at late stage of brain tumor development
and it is significantly weaker in the cranial microenvironment
compared to peripheral cancer. Thus, EPR effect may enhance
drug delivery to the brain; however, due to the late stage of
brain tumor, passive targeting alone is insufficient for effective
treatment [96,97].
6. Promising examples on selective drug delivery
systems to the lesioned brain
Recent studies using nanoparticles-based delivery systems for
the treatment of brain conditions showed clearly that it is
possible to selectively target the lesion area of the brain
when injected intravenously in preclinical animal models
[98–101]. These observations suggested that the selective
brain accumulation could be mediated through the increase
in the permeability of the BBB endothelium, a phenomenon
that could be very similar to the well-known EPR effect
observed in cancer.
These findings have been supported by imaging data that
measure the total accumulation of drug delivery systems into
the brain. Of these, I would like to highlight the detection of
[18F]-labeled liposomes with sizes between 100 and 200 nm
into a rat model of ischemic stroke using PET imaging [102]
and fluorescently labeled liposomes using ex-vivo optical ima-
ging [100]. These liposomes did not show any accumulation
into the healthy brain tissue, due to the presence of an intact
BBB in the normal areas. In one study, liposomal FK506 of
100 nm diameters was injected systematically at the reperfu-
sion time 1 h after the start of ischemia in a rat model of
stroke (Figure 3). The accumulation of liposomes in the
lesioned brain was visualized ex-vivo by detecting the fluor-
escence signal of the liposomes using optical imaging. The
areas of liposomal accumulation co-localized with infarcted
area as detected by 2,3,5-triphenyltetrazolium chloride stain.
As FK506 (tacrolimus) is a neuroprotectant drug, rats treated
with this technology were shown to have lower levels of
apoptosis and inflammation, correlating with an improved
motor function [100].
Consistent with the assumption that selective accumula-
tion of those drug delivery systems into the lesioned brain is
mediated by BBB hyperpermeability, the size of those deliv-
ery systems has been reported to have great influence on
crossing the damaged BBB. Cruz et al. demonstrated that
polylactic-co-glycolic acid nanoparticles of different sizes
showed different permeabilities into the brain following TBI
model in mice. The sizes tested were approximately 100,
200, and 800 nm, injected systemically at the time of brain
injury. As expected, the 100-nm particles showed the high-
est penetration into the injured area of the brain. The pene-
tration was less with the 200-nm particles and least with the
800-nm particles [103]. Similarly, Fukuta et al. followed the
accumulation of lipid nanoparticles injected intravenously
shortly after induction of ischemic stroke in rats.
Nanoparticles of approximately 100 nm accumulated to a
higher extent compared to those of 200 nm, while lipid
nanoparticles of 800 nm did not accumulate in the ischemic
brain regions [104].
The results of the selective increase in the accumulation of
drug molecules into the lesioned brain area after encapsulation
into nanoparticle-based delivery systems were translated further
to improve the therapeutic effect and functional outcome. In the
case of ischemic stroke, for example, these approaches could be
classified into the following categories: (1) supplement therapies
such as the delivery of ATP and oxygen that are crucial for
neuronal cell function and survival [105–110]; (2) neuroprotec-
tive agents including most of the anti-inflammatory, immuno-
modulatory drugs, and free radical scavenging agents aiming to
reduce brain damage and edema formation [100,104,111–114];
and (3) thrombolytic agents that aim to restore blood supply to
the ischemic areas of the brain [115–117]. Please note that for
thrombolytic agents, the drug will work on dissolving the clot in
the brain vasculature and therefore, crossing the BBB is not
required in this case. Among these categories, the use of neuro-
protective agents has been widely tested. In a general descrip-
tion, those agents are molecules that aim to increase the cell
resilience or recovery under disease conditions and therefore
minimize brain damage expansion. Although these molecules
are quite promising in concept, they failed clinical translation in
more than 100 phase III clinical trials with no clear added benefits
in therapeutic outcomes [118–120]. There are several reasons
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behind those disappointing results; however, the poor BBB trans-
location is, by no doubt, a crucial limiting factor.
Encapsulating therapeutic molecules into delivery systems
such as liposomes consistently displayed a better effect on
infarct volume reduction and motor recovery in animal stroke
models, and repeatedly showing selective accumulation in the
ischemic regions of the brain. An example on that is liposomal
fasudil, given directly after ischemic reperfusion to suppress
neutrophil invasion into the lesioned brain. The therapeutic
effect of this formulation was significantly higher compared to
free drug which reemphasize the importance of the drug
delivery system to provide access to the lesioned brain and
maintain appropriate drug concentration in that area [104].
The natural free radical scavenger enzyme superoxide dismu-
tase (SOD) is another neuroprotective agent that showed
better therapeutic activity for stroke after encapsulation into
liposomes. SOD helps to reduce permeability changes and
lipid peroxidation following free radical production after cere-
bral ischemia. However, in its free form, SOD has very limited
brain penetration due to its inability to cross the BBB and its
very short half-life (<6 min). Therefore, encapsulation into
nanosized drug delivery platforms was required to enhance
the antioxidant activity in the brain. In vivo experiments fol-
lowing systemic administration of SOD-loaded liposomes
demonstrated a significant increase in the enzymatic activity
in the brain and provided a significant protection against free
radicals that reflected in infarct size reduction. The high SOD
activity observed in the infarct region suggested being due to
the increase in liposomal SOD transport mediated by BBB
disruption. It is hypothesized that SOD-liposomes neuropro-
tective effect is mainly exerted on the endothelial cells; how-
ever, this might be extended to include neurons and microglia
as well since liposomal extravasation to brain parenchyma is
excepted [121–124]. Liposomal drug delivery has proved its
effectiveness in improving brain delivery and therapeutic effi-
cacy of citicoline (CDP-choline, cytidine-5-diphosphocholine)
[98,114,125–129]. Citicoline is an essential intermediate in the
synthesis of phosphatidylcholine (a major component of neu-
ronal membranes). Preclinical studies demonstrated that phar-
macological neuroprotective effect of citicoline is mediated
through the stimulation of the brain phospholipids synthesis,
inhibition of phospholipase A2 (PLA2) activation, and oxidative
stress reduction [130]. However, the clinical beneficial effect of
citicoline is highly debatable as several large populations trials
reported unclear outcomes [98,131]. This is due to the polar
nature of citicoline, which restrict its transport through BBB
[114]. A noticeable reduction in infarct volume (~30%) was
observed from liposomal citicoline as compared to free citico-
line [114]. Similar to previous studies, the improved therapeu-
tic effect observed from citicoline liposomes is hypothesized
to be related to selective accumulation into the brain as a
result of BBB disruption [129]. The beneficial therapeutic effect
of CDP-choline was also confirmed recently with serial MRI
imaging in rat model of MCAO over 7 days [114].
Promising therapeutic benefits have also been reported in
other models of lesioned brain such as in MS using long
circulating liposomal drug formulation encapsulating methyl-
prednisolone. In this study, Turjeman et al. compared the
therapeutic activity of liposomal prednisolone to that of the
free drug after multiple injections into a mouse model of MS.
Treatment was started at the onset of clinical signs (day 8 after
T-cell transfer) and continued for 3 days. Although both trea-
ted groups showed better disease improvement compared to
the control group, therapeutic benefits from liposomal formu-
lation exceed those of the free drug. That was translated into a
significant reduction in disease score, duration, and mean
Figure 3. Liposomal accumulation into rat model of ischemic stroke. PEGylated liposomes encapsulating the neuroprotective drug FK506 (FK506-liposomes) were
intravenously administered in a rat model of ischemic stroke. Stroke was induced by middle cerebral artery occlusion (MCAO) for 1 h. A) The damaged area in the
brain can be seen as paler regions on brain slices (right side) stained with TTC dye. B) In this study, FK506-liposomes were injected before the recovery of cerebral
blood flow to the brain and their selective localization in the ischemic area (right side) was followed ex-vivo by optical imaging of fluorescently labelled liposomes.
C) Liposomal delivery of the neuroprotective drug FK506 significantly suppressed the expansion of brain cells damage and D) significantly improved the motor
function score. Reproduced with permission from reference [100].
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burden. The therapeutic benefits observed from the liposomal
formulation of prednisolone compared to the free drug are
most likely due to the selective passive accumulation of lipo-
somes into the lesion site taking advantage of BBB disruption.
That was proved using Gd-based MR imaging [99]. However, it
is important to remember here that BBB disruption in MS is
highly variable and occurs most commonly during disease
relapse [73,132,133]. Therefore, care must be taken in consid-
ering the beneficial effect of nanoparticle-based drug delivery
in this case due to this variable window of opportunity.
The studies described above showed that passive targeting
of delivery systems through damaged BBB is good enough to
demonstrate a therapeutic effect; however, recent studies
have also shown that further improvement could be gained
if combined with active targeting. One example is the use of
liposomes loaded with the neuroprotective drug asialo-EPO
(AEPO), a potent antiapoptotic agent, with the aim to slow
down the rate of programmed cell death across the infarct
area. The liposomes were injected immediately after reperfu-
sion and were shown to accumulate in the ischemic regions of
the brain. These liposomes have the capacity to target neuro-
nal cells through the EPO receptors. A single dose of AEPO-
liposomes was enough to show a significant decrease in the
infarct volume [101] and to suppress the motor function def-
icit compared to untreated controls [134]. At day 7 after
reperfusion, a significant recovery from motor function deficit
and right forepaw paralysis was observed in the AEPO-lipo-
somes-treated group [134]. Similarly, the therapeutic effect of
CDP-choline liposomes could be further improved by formu-
lating actively targeted liposomes against mannose receptor
[125] or directed specifically to the peri-infarct region using
anti-HSP72 liposomal citicoline [135]. Another example is the
fluorescently labeled transferrin-targeted liposomal formula-
tion that showed maximum accumulation into the brain
when injected 1 day after cerebral ischemia. This is the time
point where the highest transferrin receptor expression was
observed. The accumulation of transferrin-targeted liposomes
is most likely to be conveyed through receptor-mediated
transcytosis process. However, the observation of liposomal
extravasation into the brain parenchyma also suggests that it
could be linked to BBB disruption at that time point [136].
The examples discussed in this section argue that using a
drug delivery technology has a clear add-on benefit compared
to the free drug. The exact mechanisms by which the selective
brain localization happens are largely unknown and require in
depth studies. BBB hyperpermeability (EPR-like effect), as an
explanation, seems satisfactory particularly for long circulat-
ing-delivery systems; however, the improved efficiency
observed from actively targeted systems compared to stan-
dard long circulating ones indicated that other factors can be
involved.
An important parameter that has not been deeply investi-
gated is the ability of those delivery systems to travel inside
the brain parenchyma after crossing the discontinued BBB.
The heterogenous nature of the BBB disruption and the pre-
sence of BM could act as a second barrier that limits the
nanoparticles access from the blood to the brain. This phe-
nomenon has been reported before by Moldoon et al. by
studying the brain localization of two different types of iron-
oxide nanoparticles: Feridex and MION. Both nanoparticles
have comparable size but differ only in surface coating as
Feredix is known to be opsonized quite quickly compared to
MION. The distribution of those nanoparticles in the brain was
assessed by MRI, after systemic administration of Feredix and
MION following osmotic disruption of the BBB. It was very
interesting to observe that at the histological level, both
nanoparticles demonstrated very distinct distribution in the
brain despite both showing homogenous brain distribution
with MRI. Histological observation showed that Feredix nano-
particles were mainly trapped around the brain blood vessels
in the space between BECs and BM; on the contrary, MION
nanoparticles were found within cell bodies throughout the
disrupted hemisphere [137]. This study emphasizes on the
importance to complement bulk imaging techniques (MRI
and PET) with histological analysis to assess cellular localiza-
tion of the delivery system after crossing the disrupted BBB.
Similar evidences were observed from three recent in vivo
studies examined the capacity of nanoparticles to extravasate
the brain parenchyma after induced entry into the brain by
transient opening of BBB using focused ultrasound. These
studies elucidated that the capacity of nanoparticles to travel
inside the brain parenchyma is highly dependent on the size
and surface properties of the nanoparticles that had a signifi-
cant impact on their localization relative to the vascular BM
[138–140]. Nanoparticles with small size and/or hydrophilic
surface (<120 nm) have higher ability to travel away from
the blood vessels compared to large and/or negatively
charged nanoparticles. The barrier effect of BM described
above is based on experimental evidence from studies per-
formed in healthy animals where no changes in BM and ECM
composition are expected. Little is known how BM and ECM
modification in different brain lesions could impact nanopar-
ticles distribution in the brain. This is a crucial point that
deserves further investigation.
The release profile of drug delivery systems applied for
treatment of brain disorder has not been systematically inves-
tigated either. Moreover, the actual release profile of drug
molecules once in the brain has been hardly studied before.
However, based on the knowledge generated from in vitro
studies and other diseases like peripheral cancer, it is expected
that drug release will be dependent on several parameters.
These include the type of drug delivery system, diffusion rate
of drug through the lipid bilayer (liposomes) or polymeric
matrix (polymeric nanoparticles), biodegradable properties of
polymers, the lipid composition and rigidity for liposomes
nanoparticles, nanoparticles size, and the interaction with
plasma protein (before getting access into the brain) and
ECM proteins in the brain.
The toxicity related to the nanoparticle-based drug delivery
systems in the context of brain delivery is still an area that
requires more specific investigations. Most of drug delivery
systems used for brain delivery have been tested before for
other applications and thus, limited neurological toxicity is
expected particularly for those already in clinical use such as
liposomes and polymeric nanoparticles. The toxicity profile
will be very much dependent on the nanoparticles composi-
tion, surface properties, and concentration. Previous studies
using liposomes and polymeric nanoparticles have not
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reported severe toxicological changes following accumulation
in the brain. Few studies reported the susceptibility to neuro-
toxicity and seizure following MR imaging with gadolinium in
preclinical models. This effect was dose dependent and corre-
lated with repeated administration [141].
7. Benefits of nanoparticle-based delivery systems
compared to other CNS drug delivery strategies
Several approaches to enhance drug transport to the brain
have been under development for the past few decades.
Although enhanced BBB entry is the main aim for those
approaches, other parameters are likely to be equally impor-
tant. These include improved pharmacokinetic profile of the
drug, achieving site-specific delivery, enzymatic stability, and
reduced systemic toxicity.
Ligand-targeted drug conjugates have proved promising
results to enhance brain delivery. Those are designed in
away that the binding of the ligand will be on a region that
is not directly involved in the binding of endogenous sub-
strates. A promising example on that is the utilization of
OATP/Oatp influx transport systems to enhance drug delivery
for ischemic stroke. Statins (e.g. pitavastatin and rosuvastatin)
are substrate for OATPs (Oatp1a4) influx system that is
expressed on the brain microvascular endothelium [142].
OATP/Oatp isoforms have also a very important role in the
brain delivery of opioid analgesic peptides (e.g. deltorphin II)
for pain management purposes [143]. Interestingly, Thompson
et al. have reported, in rat model of cerebral ischemia, that
functional expression of Oatp1a4 is enhanced after hypoxia
[144]. Moreover, microvascular expression and activity of
Oatp1a4 at the BBB can be further increased through inhibi-
tion of TGF-β signaling [144,145]. Since TGF-β1 expression is
known to be enhanced after cerebral ischemia [146], pharma-
cological inhibition of TGF-β pathway could have very critical
effect to enhance the function of Oatps influx transporter and
ultimately increase CNS drug delivery. Despite showing pro-
mising results, care must be taken in the design and evalua-
tion of therapeutics that act through these pathways (Table 2).
First, ligand–drug conjugates should have desirable pharma-
cokinetic properties and maintain drug activity and ligand
targeting capability. Second, ligand–drug substrates for one
transport system e.g. OATP/Oatp can also transported by at
least one additional transporter (e.g. P-gp efflux transporter)
and thus, the overall accumulation in the brain may be
reduced. Third, the broad nature of many of these transporters
and the interference with endogenous substrates can also
pose another obstacle toward clinical translation. Likewise,
the exact mechanism of BBB permeation of drug-conjugates
can be sometimes difficult to predict based on theoretical
principles only. For example, attachment of glucose moiety
to a peptide can improve the transport across the BBB, but this
is not necessarily due to the peptide ability to use the BBB
glucose transporter (GLUT1). Finally, ligand–drug conjugates
can accumulate in different region of the brain (disease not
specific) that may cause undesirable side effect. Moreover,
changes in the expression of certain transport systems in the
brain in some diseases have critical impact on the transloca-
tion ability of ligand–drug conjugates into the brain and
perhaps cause heterogenous distribution [42,147].
Nanoparticle-based drug delivery systems, on the other
hand, have less impact on the pharmacological properties of
the drug and the pharmacokinetic profile mimics that of the
drug delivery system. The accumulation in the lesioned brain
is principally selective to the regions of damaged BBB within
the lesioned brain [100,103]. Therefore, this approach could
have higher degree of disease specificity compared to ligand-
targeted therapies. Additionally, nanoparticle-based drug
delivery systems offer other benefits in terms of the drug
stability and ability to modulate drug release [80]. However,
in order for the drug to act on brain tissues, complete shut-
tling into the brain parenchyma needs to follow. Several para-
meters can affect this process such as (a) the BECs signaling
pathways to allow complete transcytosis into the brain, (b) the
ability of drug delivery systems to pass through the BBB BM
and travel through the brain ECM. This hindrance effect has
been demonstrated before with iron oxide nanoparticles [137].
However, due to the complex nature of ECM and the signifi-
cant modification reported in many neurological conditions,
in-depth studies are warranted to understand the exact nature
of these limiting factors.
8. Expert opinion
Lesioned brain disorders such as cerebral ischemia, TBIs, and
postoperative brain tumors represent a leading cause of death
and disability worldwide. Yet, treatment options are extremely
limited and represent an area of unmet clinical need. A sig-
nificant problem with these disorders is the long-term disabil-
ity that exceeds that caused by any other chronic illnesses. The
resulting long-term disability means that those who survive
may require long-term careers. As a result, the economic costs
of those disorders are very high. For example, only the burden
of stroke on economy is estimated to cost about £8.9 billion a
Table 2. Advantages and disadvantages of nanoparticles-based CNS drug delivery compared to ligand-drug conjugates.
Parameters Ligand–drug conjugates Nanoparticles-based CNS drug delivery
Pharmacological activity Structural modification may affect pharmacological
activity of the final product
No modification to the pharmacological properties is expected;
however, drug release is required
Pharmacokinetic profile Pharmacokinetic profile of the final product can be
different to that of drug and targeting ligand
Mimics drug delivery system pharmacokinetic profile
Undesirable effects Brain targeting is not specific to the lesioned-brain and
can be heterogenous/(disease nonspecific)
Accumulation is mainly restricted to BBB damage area with in the
lesioned brain/(disease specific)
Translocation into the brain Binding affinity must be retained to allow binding to BBB
transposers
Shuttling through the BEC into the brain parenchyma is necessary
followed by the ability to travel through BM and ECM
BBB: blood–brain barrier; BEC: brain endothelial cells; BM: basement membrane; ECM: extracellular matrix.
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year in the United Kingdom and with an ageing population,
this figure is likely to increase significantly [148]. Therefore,
there is an urgent need for efficient use of resources toward
the development of cost-effective treatment of such condi-
tions. The BBB is formed by specialized capillary endothelium
that excludes more than 98% of small molecule neurothera-
peutics and almost all large molecular drugs. Because of the
poor accessibility of therapeutic molecules to the brain, there
currently have very few effective treatments for most of the
lesioned brain disorders [42]. The development of effective
pharmacological treatment for lesioned brain is facing
repeated translational failure, despite the tremendous success
that has been made in molecular neuroscience [118]. As a
matter of fact, many new neurotherapeutics that have been
discovered carry the potential to treat many brain disorders, if
an effective technology to cross the BBB is in place. Therefore,
the development of new methodologies in this area can give
new hope to those therapeutics.
The BBB plays an essential role in the stability and homoeos-
tasis of the brain tissues. However, the BBB structure is in a
dynamic change in several brain disorders. This leads to a high
number of pathophysiological processes which contribute to the
spread of damage over a longer period. Understanding the
molecular basis and the time frame of such changes can bring
upon new opportunities for brain drug delivery and open a new
market for CNS therapeutics. This would not be accomplished
without collaborative efforts between biological neuroscientist,
drug delivery scientists, and clinicians to link those pathophysio-
logical structural changes of brain endothelium to drug transport
across the BBB and most importantly to put this in a timeframe
that is fundamental for practical clinical translation.
In the treatment of ischemic stroke, for example, lipo-
somes and other nanoparticles have shown great success
in facilitating a wide range of pharmaceutical therapeutics to
pass through the damaged BBB during the first few hours
after reperfusion and act on the ischemic regions of the
brain, reducing infarct sizes and helping to prevent further
brain damage. The nanoparticles allow for higher circulation
times and bioavailability of their encapsulated drugs to the
brain tissues that would otherwise inefficiently crossed the
BBB. However, these studies concentrated only on the very
early stages after brain ischemia and, therefore, did not
address the long-term pathological effects and the practi-
cality of clinical translation. Neuroprotective drugsʼ main aim
is to increase the therapeutic window compared to throm-
bolytic therapies. However, this was not the case in those
studies as the focus was on intravenous injection around the
reperfusion time or shortly after, which, limits their potential
use to the first few hours after ischemic insult. A greater
understanding of the BBB disruption and the timeframe of
its breakdown in association with brain disorders is needed
to fully achieve the potential of this approach. Furthermore,
a critical factor in the clinical translation of this approach is
the variability in the time-window of BBB disruption and
recovery after different neurological conditions such as
stroke and MS. This point is very critical for pharmacological
treatments that require sustained drug exposure due to the
limited window of BBB opening. Thus, in this case, the
design of nanoparticle-based drug delivery with slow drug
release over longer time would be more appropriate to
ensure that the treatment can outlast the window of BBB
opening. The residency time of the drug delivery system in
the brain and mechanism of clearance are also very impor-
tant parameters that are yet to be investigated. Moreover,
care must be taken in the translation of preclinical findings
into clinical setting due to several fundamental differences
between the preclinical model brains compared to humans.
Anatomical differences, size and volume variation are among
many factors that could overestimate the therapeutic bene-
fits of this approach.
There are several questions that still need to be answered.
First, the mechanism by which those nanoparticles gain access
through the damaged BBB and if this is different from one
disorder to another or if those mechanisms change over time
in the same disorder, and, second, if those nanoparticles able
to pass the damaged BBB and reach the brain parenchyma,
what their cellular fate and mechanism of drug release are.
Third, the safety and impact of nanoparticles of on brain
parenchyma is still an area that requires extensive investiga-
tion. The answers stay unclear at present and further work is
required to understand these processes in more details.
One should also not dismiss the challenges that may
accompany this approach. Although BBB disruption has been
reported in several neurological disorders, the process of dis-
ruption is not homogeneous as regions of intact and disrupted
BBB coexist. These observations were reported in clinical and
preclinical studies and largely depend on the severity of the
neurological condition. Based on that, inhomogeneous treat-
ment may happen and could limit the therapeutic progress.
Therefore, it is critical to understand the mechanisms behind
BBB disruption for each neurological condition to be able to
develop strategies to overcome these limitations.
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